Search

Displaying results 1641 - 1650 of 3601 in total
  1. Target

    Prostaglandin E2 Receptors

    go.drugbank.com/bio_entities/BE0010100
    TargetHumans

    Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. … Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system.

    Polypeptides: Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtypeSynonyms: PGE receptor EP1 subtype, Prostanoid EP1 receptor
  2. Drug

    Opium

    go.drugbank.com/drugs/DB11130
    ApprovedIllicit

    Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative a...

    Mixtures: Donnagel-PG Liq, Donnagel-PG CapCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Indication

    Esophageal Candidiasis

    go.drugbank.com/conditions/DBCOND0040096
    Drugs: Anidulafungin · Caspofungin · Fluconazole · Itraconazole · Micafungin · Posaconazole +1 more
    Synonyms: Candidiasis: [OS NOS] or [granuloma] or [intestinal] or [oesophageal] or [rectal])
  4. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    It is a high affinity, high efficacy agonist of the progesterone receptor (PR) with a much more selective binding profile relative to most conventional progestins. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.

  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to ...

  7. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the d...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker. APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. Elevated APRIL levels are often observed in inflammatory disord...

  9. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  10. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx...